Efficacy of idebenone in Duchenne muscular dystrophy

The Lancet

Volumn 385, Issue 9979, 2015, Pages 1704-1706

  Mercuri, Eugenio ^a   Muntoni, Francesco ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IDEBENONE; ANTIOXIDANT; UBIQUINONE;

AGE; DRUG EFFICACY; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; EXPERIMENTAL THERAPY; FORCED VITAL CAPACITY; HUMAN; INTENTION TO TREAT ANALYSIS; MAXIMUM EXPIRATORY PRESSURE; MAXIMUM INSPIRATORY PRESSURE; MOTOR PERFORMANCE; MULTICENTER STUDY (TOPIC); MUSCLE STRENGTH; NOTE; OUTCOME ASSESSMENT; PEAK COUGH FLOW; PEAK EXPIRATORY FLOW; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FUNCTION; RESPIRATORY TRACT PARAMETERS; THORAX WALL; ANALOGS AND DERIVATIVES; MALE; MUSCULAR DYSTROPHY, DUCHENNE; RESPIRATION DISORDERS;

ANTIOXIDANTS; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; RESPIRATION DISORDERS; UBIQUINONE;

EID: 84929032189     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60758-9     Document Type: Note

References (13)

1. GM Buyse, T Voit, U Schara for the DELOS Study Group Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial Lancet 2015 published online April 21. http://dx.doi.org/10.1016/S0140-6736(15)60025-3
2. E Mercuri, F Muntoni Muscular dystrophy: new challenges and review of the current clinical trials Curr Opin Pediatr 25 2013 701 707
3. S Lynn, A Aartsma-Rus, K Bushby et al. Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy Neuromuscul Disord 25 2015 96 105
4. S Cirak, V Arechavala-Gomeza, M Guglieri et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study Lancet 378 2011 595 605
5. K Bushby, R Finkel, B Wong et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy Muscle Nerve 50 2014 477 487
6. NM Goemans, M Tulinius, JT van den Akker et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy N Engl J Med 364 2011 1513 1522
7. M Pane, ES Mazzone, S Sivo et al. Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes PLoS One 9 2014 e108205
8. E Henricson, R Abresch, JJ Han et al. The 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year PLoS Curr 2013 10.1371/currents.md.9e17658b007eb79fcd6f723089f79e06 published online July 8.
9. M Haas, V Vlcek, P Balabanov et al. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene Neuromuscul Disord 25 2015 5 13
10. A Hahn, JR Bach, A Delaubier, A Renardel-Irani, C Guillou, Y Rideau Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne muscular dystrophy Arch Phys Med Rehabil 78 1997 1 6
11. J Hull, R Aniapravan, E Chan et al. British Thoracic Society guideline for respiratory management of children with neuromuscular weakness Thorax 67 suppl 1 2012 i1 40
12. M Pane, ES Mazzone, L Fanelli et al. Reliability of the performance of upper limb assessment in Duchenne muscular dystrophy Neuromuscul Disord 24 2014 201 206
13. LCA Servais, N De Coninck Upper limb evaluation in non-ambulatory patients with neuromuscular disorders Neuromuscul Disord 23 2013 139 148